Published in Br J Clin Pharmacol on August 01, 2013
Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus. Gene Ther (2014) 0.95
MicroRNA as therapeutic targets for treatment of depression. Neuropsychiatr Dis Treat (2013) 0.81
Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics. Appl Transl Genom (2015) 0.79
Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector. Hum Gene Ther (2014) 0.78
Widening Phenotypic Spectrum of AADC Deficiency, a Disorder of Dopamine and Serotonin Synthesis. JIMD Rep (2014) 0.78
An Autogenously Regulated Expression System for Gene Therapeutic Ocular Applications. Sci Rep (2015) 0.77
Strategies for targeting primate neural circuits with viral vectors. J Neurophysiol (2016) 0.76
Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. Viruses (2014) 0.76
Tet-On Systems For Doxycycline-inducible Gene Expression. Curr Gene Ther (2016) 0.75
Biological therapies: a long way on from Jenner. Br J Clin Pharmacol (2013) 0.75
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
Transcriptional activation by tetracyclines in mammalian cells. Science (1995) 13.90
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev (2001) 9.14
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol (1989) 6.69
Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A (2000) 5.99
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A (1996) 5.93
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther (2003) 4.92
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol (1996) 4.83
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 4.52
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther (2001) 4.35
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis (2009) 4.27
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene (1983) 4.15
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol (2003) 3.74
Current prospects for RNA interference-based therapies. Nat Rev Genet (2011) 3.63
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther (2010) 3.37
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A (2003) 3.31
Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res (1995) 3.24
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol (2006) 3.02
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res (1997) 2.90
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother (2006) 2.84
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther (2006) 2.67
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther (2007) 2.64
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther (2012) 2.42
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 2.42
Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science (1997) 2.40
A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol (2010) 2.39
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther (2007) 2.17
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol (2004) 2.12
Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol (2003) 2.07
Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther (2008) 2.06
Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther (1998) 2.06
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol (2000) 2.00
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther (2003) 1.94
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci U S A (1997) 1.91
Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol (2004) 1.85
Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol (2000) 1.82
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther (2011) 1.79
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther (2010) 1.77
Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol (1998) 1.75
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci (2000) 1.74
Immune responses to AAV in a phase I study for Canavan disease. J Gene Med (2006) 1.74
Characterization of adeno-associated virus genomes isolated from human tissues. J Virol (2005) 1.72
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol (2003) 1.72
Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A (1999) 1.72
Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther (2006) 1.71
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther (2012) 1.70
Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol (1998) 1.68
Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther (2009) 1.66
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther (2009) 1.61
Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther (2002) 1.60
Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol (2011) 1.57
Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther (2009) 1.57
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther (2012) 1.55
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther (2012) 1.55
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 1.52
Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol (2007) 1.52
Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol (2002) 1.49
Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther (2006) 1.42
Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 1.40
A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One (2009) 1.40
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci (2004) 1.38
Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med (2006) 1.35
Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther (2001) 1.35
Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol (2000) 1.32
Silencing and un-silencing of tetracycline-controlled genes in neurons. PLoS One (2007) 1.32
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther (2010) 1.31
Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis (2004) 1.31
The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther (2012) 1.30
MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther (2010) 1.30
Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology (2003) 1.30
Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys (2004) 1.78
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med (2014) 1.64
Sepsis is associated with altered cerebral microcirculation and tissue hypoxia in experimental peritonitis. Crit Care Med (2014) 1.60
Accuracy of brain multimodal monitoring to detect cerebral hypoperfusion after traumatic brain injury*. Crit Care Med (2015) 1.55
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Patterns of neurovascular compression in patients with classic trigeminal neuralgia: A high-resolution MRI-based study. Eur J Radiol (2009) 1.48
Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of meningioma. Acta Neurochir (Wien) (2014) 1.39
Cerebral microcirculation is impaired during sepsis: an experimental study. Crit Care (2010) 1.39
Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med (2004) 1.35
Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis (2004) 1.31
Brain stem metastases treated with radiosurgery: prognostic factors of survival and life expectancy estimation. Surg Neurol (2008) 1.20
Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg (2007) 1.18
Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther (2006) 1.17
Preliminary experience with the enterprise stent for endovascular treatment of complex intracranial aneurysms: potential advantages and limiting characteristics. Neurosurgery (2008) 1.14
Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res (2009) 1.13
Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery (2009) 1.03
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg (2006) 0.99
Chronic subdural hematomas treated by burr hole trepanation and a subperiostal drainage system. Neurosurgery (2009) 0.98
Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis (2005) 0.98
Clinical evaluation of targeting accuracy of gamma knife radiosurgery in trigeminal neuralgia. Int J Radiat Oncol Biol Phys (2007) 0.97
Standardization of terminology in stereotactic radiosurgery: Report from the Standardization Committee of the International Leksell Gamma Knife Society: special topic. J Neurosurg (2014) 0.96
Synovial cysts of the lumbar spine: surgery-related results and outcome. J Neurosurg (2003) 0.95
Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther (2013) 0.94
Retractable self-expandable stent for endovascular treatment of wide-necked intracranial aneurysms: preliminary experience. Neurosurgery (2006) 0.93
Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. J Neurosurg Pediatr (2010) 0.92
Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther (2014) 0.91
Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging (2006) 0.91
Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of arteriovenous malformations and acoustic neuromas. Radiother Oncol (2012) 0.90
Influence of nerve radiation dose in the incidence of trigeminal dysfunction after trigeminal neuralgia radiosurgery. Neurosurgery (2007) 0.90
Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg (2004) 0.90
Cerebral extracellular lactate increase is predominantly nonischemic in patients with severe traumatic brain injury. J Cereb Blood Flow Metab (2013) 0.89
Brain lactate metabolism in humans with subarachnoid hemorrhage. Stroke (2012) 0.89
Clinical interest of integrating positron emission tomography imaging in the workup of 55 children with incidentally diagnosed brain lesions. J Neurosurg Pediatr (2010) 0.88
Cerebral aneurysm exclusion by CT angiography based on subarachnoid hemorrhage pattern: a retrospective study. BMC Neurol (2011) 0.88
Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J Gene Med (2009) 0.87
Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. Int J Radiat Oncol Biol Phys (2006) 0.86
Recombinant AAV delivery to the central nervous system. Methods Mol Biol (2011) 0.86
Irradiation of cochlear structures during vestibular schwannoma radiosurgery and associated hearing outcome. J Neurosurg (2007) 0.86
Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging (2006) 0.85
Gamma knife surgery for idiopathic trigeminal neuralgia performed using a far-anterior cisternal target and a high dose of radiation. J Neurosurg (2004) 0.85
PET imaging in the surgical management of pediatric brain tumors. Childs Nerv Syst (2007) 0.84
Selective image-guided venous sinus exposure for direct embolization of dural arteriovenous fistula: technical case report. Surg Neurol (2007) 0.84
Observations of intracranial neoplasms treated with gamma knife radiosurgery. J Neurosurg (2002) 0.84
Minimally invasive spinal arthrodesis in osteoporotic population using a cannulated and fenestrated augmented screw: technical description and clinical experience. Minim Invasive Surg (2012) 0.83
Differential transgene expression profiles in rat brain, using rAAV2/1 vectors with tetracycline-inducible and cytomegalovirus promoters. Hum Gene Ther (2008) 0.83
Internal carotid occlusion following gamma knife radiosurgery for cavernous sinus meningioma. Stereotact Funct Neurosurg (2007) 0.82
Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg (2003) 0.82
Endovascular treatment of middle cerebral artery aneurysms. Neurocrit Care (2006) 0.82
Patterns of pain-free response in 497 cases of classic trigeminal neuralgia treated with Gamma Knife surgery and followed up for least 1 year. J Neurosurg (2012) 0.81
Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery (2005) 0.81
Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors. Hum Gene Ther (2012) 0.81
Radiosurgery for trigeminal neuralgia. Prog Neurol Surg (2007) 0.80
Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med (2007) 0.80
Three-dimensional Gaussian model to define brain metastasis limits on 11C-methionine PET. Radiother Oncol (2008) 0.80
Delayed presentation of deep penetrating trauma to the subaxial cervical spine. Eur Spine J (2014) 0.80
Pathological findings following trigeminal neuralgia radiosurgery. Prog Neurol Surg (2007) 0.80
Morphological observations in brain arteriovenous malformations after gamma knife radiosurgery. Prog Neurol Surg (2012) 0.80
Combination of functional magnetic resonance imaging-guided neuronavigation and intraoperative cortical brain mapping improves targeting of motor cortex stimulation in neuropathic pain. Neurosurgery (2008) 0.79
An adeno-associated virus-based intracellular sensor of pathological nuclear factor-κB activation for disease-inducible gene transfer. PLoS One (2013) 0.79
A statistical shape model of the human second cervical vertebra. Int J Comput Assist Radiol Surg (2014) 0.79
Comparison of functional MR imaging guidance to electrical cortical mapping for targeting selective motor cortex areas in neuropathic pain: a study based on intraoperative stereotactic navigation. AJNR Am J Neuroradiol (2005) 0.79
Experimental analysis of radiation dose distribution in radiosurgery. II. Dose fall-off outside the target volume. Stereotact Funct Neurosurg (2009) 0.78
Combination of functional magnetic resonance imaging-guided neuronavigation and intraoperative cortical brain mapping improves targeting of motor cortex stimulation in neuropathic pain. Neurosurgery (2005) 0.78
Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A histopathological and immunohistochemical study. J Neurosurg (2005) 0.78
Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. Cell Transplant (2008) 0.78
The Very Long-Term Outcome of Radiosurgery for Classical Trigeminal Neuralgia. Stereotact Funct Neurosurg (2016) 0.78
Cerebral metastases pathology after radiosurgery: a multicenter study. Cancer (2006) 0.78
Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Childs Nerv Syst (2004) 0.78
Minocycline-induced activation of tetracycline-responsive promoter. Neurosci Lett (2003) 0.77
Experimental analysis of radiation dose distribution in radiosurgery: I. Dose hot spot inside target volume. Stereotact Funct Neurosurg (2009) 0.77
Occipitoaxial spinal interarticular stabilization with vertebral artery preservation for atlantal lateral mass failure. J Neurosurg Spine (2014) 0.77
Modern Gamma Knife radiosurgery of vestibular schwannomas: treatment concept, volumetric tumor response, and functional results. Neurosurg Rev (2014) 0.77
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. Cancer Immunol Immunother (2010) 0.77
Radiosurgical pathology of brain tumors: metastases, schwannomas, meningiomas, astrocytomas, hemangioblastomas. Prog Neurol Surg (2007) 0.77
Neurovascular compression anatomy and pain outcome in patients with classic trigeminal neuralgia treated by radiosurgery. Neurosurgery (2008) 0.77
Magnetic resonance angiography image guidance for the microsurgical clipping of intracranial aneurysms: a report of two cases. Neurol Res (2004) 0.77
Histopathology of brain metastases after radiosurgery. Prog Neurol Surg (2012) 0.76
Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells. Neuroreport (2005) 0.76
Eosinophilic meningitis following incomplete resection of a meningeal hydatid cyst. Scand J Infect Dis (2003) 0.75
Effect of beam channel plugging on the outcome of gamma knife radiosurgery for trigeminal neuralgia. Int J Radiat Oncol Biol Phys (2006) 0.75
Kernohan's notch and misdiagnosis of disorders of consciousness. BMJ Case Rep (2014) 0.75